Biological Activity
BGC-20-1531 (PGN 1531) free base is a potent and selective prostanoid EP4 receptor antagonist, with a pKB of 7.6. BGC-20-1531 free base has the potential for the research of migraine headache[1].
BGC-20-1531 free base competitively antagonized PGE2-induced vasodilatation of human middle cerebral (pKb=7.8) and meningeal (pKb=7.6) arteries, but had no effect on responses induced by PGE2 on coronary, pulmonary or renal arteries[1].
BGC-20-1531 free base (1-10 mg/kg; i.v.) causes a dose-dependent antagonism of the PGE2-induced increase in canine carotid blood flow[1].
References
[1]. Maubach KA, et al. BGC20-1531, a novel, potent and selective prostanoid EP receptor antagonist: a putative new treatment for migraine headache. Br J Pharmacol. 2009;156(2):316-327.
